Multi-Cancer Early Detection Tests

სკრინინგი · §135

A blood test marketed as a screen for fifty cancers at once — including the deadly ones nothing else catches. The biology is real: tumours of the pancreas, ovary, liver and a dozen others shed DNA into the bloodstream that the test can pick up. The catch: the one randomised trial built to prove the test saves lives missed its target in June 2026, and the bill runs about $949 a year out of pocket. Here's what it does well, what it doesn't, and how to think about whether it's worth ordering.

Decide · Yearly Evidence Mixed თავი სკრინინგი

The biology is sound and the test catches some real cancers early. The hesitation is also sound: the trial built to prove it saves lives missed its goal, the cost is about a thousand dollars a year out of pocket, and a positive result triggers months of follow-up scans. For most people this is a decide-with-your-doctor question. The strongest case is in adults over fifty with smoking history or a strong family pattern of cancer; the weakest is in healthy under-forties without risk factors.

Cancer cells die faster than healthy ones, and when they break up they leak fragments of their DNA into the bloodstream. The test reads those fragments — specifically the pattern of small chemical tags called methylation that turn genes on and off. A tumour's methylation pattern is messy in a specific way, and the mess carries enough information to guess which organ the cancer came from. The most-used version, GRAIL's Galleri, screens for one shared cancer signal across more than fifty tumour types, and when it finds one it names the one or two most likely body sites for the workup that follows Klein 2021.

The biology has a hard floor. A tumour smaller than a centimetre across doesn't shed enough DNA for the test to find it reliably. That's why sensitivity climbs from around 17% at stage I to about 90% at stage IV — the test is good at finding cancer when there's plenty of it, and much less good when there isn't Klein 2021. The question every screening tool eventually has to answer is whether it finds the cancer earlier than waiting for symptoms would have.

What the trials actually show

Four big studies have shaped the picture, and they don't all point the same way.

The first prospective trial in healthy adults was PATHFINDER — six thousand people over fifty across seven US health systems. The test flagged 1.4% of them with a cancer signal, and of those flagged, 38–43% actually had cancer. For people whose result turned out to be a false alarm, getting to "no, you don't have cancer" took a median of five months of follow-up scans and waiting Schrag 2023. A larger follow-up sharpened those numbers — the chance that a positive result was truly cancer climbed to about 62%, and early-stage cancers were found in roughly three out of every thousand people screened.

Then in June 2026 the result that was supposed to settle the question came in: NHS-Galleri, 142,250 adults across England, three annual rounds of screening, the world's first randomised controlled trial of this kind of test. It missed its main goal. Across all cancers combined, the drop in late-stage diagnoses wasn't statistically meaningful. Focused just on the twelve deadliest cancers, the picture was more encouraging: stage IV diagnoses down 22–26%, cancers diagnosed in emergency presentations down 25%, early-stage diagnoses up 16% NHS-Galleri 2026.

A fourth study, SYMPLIFY, looked at people who already had cancer symptoms and were being referred for diagnostic workup — not healthy screening. The test caught about three-quarters of those cancers, and the number sometimes ends up in marketing brochures as evidence of high accuracy Nicholson 2023. It is accurate in that population — but those people were already symptomatic, and the test performs noticeably worse as a screen in healthy adults.

Why anyone is trying to build this

Roughly two thirds of cancer deaths in the US come from cancers that have no recommended screening — pancreas, ovary, liver, oesophagus, stomach, most cancers of the head and neck USPSTF 2024. The five we do screen for — breast, cervical, colorectal, prostate, lung in heavy smokers — cover the other third. The rest mostly turn up the way they always have: vague symptoms that didn't add up at month three, a scan ordered at month six, a stage III or IV diagnosis on a Tuesday afternoon. For pancreatic and oesophageal cancer at stage IV, five-year survival sits in the single digits.

That gap is what this kind of test exists to address. The decision isn't this test instead of your colonoscopy — it's whether to add it on top, accepting the cost and the false-positive risk, for a chance to catch one of the cancers nothing else is looking for.

How you'd actually get one

By prescription only in the US — there's no over-the-counter version. A primary care doctor, a concierge clinic, or some employer wellness programs can order it. One venous blood draw, no fasting, results in about two weeks.

The list price is $949; a reduced self-pay rate of around $799 is common, and GRAIL offers up to $350 in financial assistance for low-income patients. Most private insurance does not cover it, and Medicare does not. TRICARE covers it for eligible service members aged 50 and over with documented elevated risk — smoking history, family history, or service-related exposure — but as of mid-2025 limited to once per lifetime rather than annually. HSA and FSA dollars qualify in most cases.

If the result is negative, you go back to your usual screening. If the result flags a cancer signal, the test names the one or two most likely body sites and your doctor orders imaging — typically a PET-CT or whole-body MRI — followed by targeted biopsy if anything turns up. In trial conditions, true positives took a median of 57 days to a confirmed diagnosis; false positives took 162 days to a clean result Schrag 2023.

What the marketing leaves out

Four claims to read carefully:

"Screens for fifty cancers" is not the same as catching them. The test detects a signal across more than fifty cancer types when one is present, but sensitivity for prostate and kidney is below 20%, and brain tumours don't shed enough DNA into the blood to register at all Klein 2021. The headline number is what the test can detect when cancer is there — not its screening power for any single cancer.

"99.5% specificity" doesn't translate to "1 false positive per 200 healthy people." When the chance of cancer in a given year is small — a few in a thousand among asymptomatic 50-year-olds — even a very specific test produces a meaningful number of false positives relative to true ones. About 38–52% of positive results across the major trials turned out not to be cancer Schrag 2023 NHS-Galleri 2026.

A negative result is not a clean bill. The test misses roughly 60–70% of cancers in any given screening round, and it misses the early-stage cancers in particular — the ones it was designed to find. A negative result means the test didn't find a signal; it doesn't mean there's nothing there NHS-Galleri 2026.

"Catching cancer earlier" doesn't automatically mean "fewer cancer deaths." Some cancers grow slowly enough that catching them earlier just means more years labelled as a cancer patient, without changing when or whether the cancer ultimately kills you. That is partly what the NHS-Galleri primary-endpoint miss is about: the stage shift is real, but it doesn't yet prove a mortality benefit NHS-Galleri 2026.

Where it goes wrong in practice

Three characteristic ways this test goes wrong for the individual using it:

The false-positive cascade. A positive result triggers imaging — usually a PET-CT or whole-body MRI — sometimes followed by endoscopy or biopsy. In the PATHFINDER trial, 92% of people with a positive result underwent at least one imaging scan, and 30% of false-positive workups included an invasive procedure Schrag 2023. The median time from positive test to a confirmed "no, you don't have cancer" was about five months. Those five months are spent thinking you might have cancer.

The wrong-organ chase. When the test detects a signal, it names the one or two most likely body sites. It's right most of the time, but wrong in about 8–15% of true positives. When it's wrong, the workup looks in the wrong place first, and the real primary tumour shows up only after several rounds of clean scans Pangaluri 2025.

The false negative that delayed the diagnosis. A negative result in someone who actually has an early cancer buys them another year of false reassurance — and the symptoms that would have prompted earlier investigation get dismissed as "probably nothing, my test was clear last March." Most of the cancers found within twelve months of testing in the major trials were caught by something other than the test Schrag 2023.

Not many absolute contraindications — it's a blood draw. The exceptions are biological situations that confuse the test, plus one psychological consideration worth thinking about before you book.

What you'd be doing instead

The strongest alternative isn't another version of this test — it's making sure the standard adult cancer screening schedule you already qualify for is actually current. Colonoscopy or a stool-based test (FIT or Cologuard), mammography on schedule, cervical screening, low-dose chest CT if your smoking history qualifies you, a PSA conversation with your doctor. Those tests catch the cancers responsible for a third of US cancer deaths, and adherence is far from universal — the gap between "what's recommended" and "what people actually get" is bigger than the gap this test would close USPSTF 2024.

The other option is waiting. GRAIL submitted the test to the FDA in January 2026, and the first regulatory decision is expected in 2026 or 2027. If the FDA approves it and Medicare covers it, the price will likely fall and the standard-of-care position will be settled. For someone deciding right now, "wait for the answer" is a defensible call.

If it works for you, what does that look like

Three timescales:

Day of the result, if it's negative: not much. You go on with your normal life and your usual cancer screening still applies. The test isn't a substitute for any of it.

Months one to six, if positive and confirmed: a stage I or II diagnosis of a cancer that mostly presents at stage III or IV. Surgery instead of palliative chemotherapy. For pancreatic cancer caught at stage I, five-year survival is around 40%, versus 3% at stage IV. For ovarian, roughly 90% at stage I versus 30% at stage IV.

Five to ten years out, if your situation matches the trial population: a small absolute reduction in cancer mortality. If the NHS-Galleri stage shift translates to mortality the way prior screening programs have, the order of magnitude is one to two lives saved per thousand people screened across a decade — but that translation hasn't been demonstrated yet, and the mortality data won't be mature until around 2030 NHS-Galleri 2026.

The honest summary: the payoff is real and meaningful for the small fraction of people whose test catches an early-stage version of a deadly cancer. For the other 996 out of 1,000 screened in any given year, the payoff is some combination of mild reassurance, a false-positive scare, or nothing at all.

Adjacent topics worth a look: making sure your USPSTF-recommended screenings are current (colonoscopy, mammography, cervical screening, low-dose chest CT for smokers), genetic testing for hereditary cancer syndromes if your family history fits the pattern, and monitoring tests for people already diagnosed and treated for cancer (a different kind of liquid biopsy with different evidence behind it).

Related in the handbook

Alternatives

— This blood test doesn't replace the proven screens — the standard cancer schedule is the established, evidence-backed baseline it sits on top of.

— Colon cancer already has a proven screen; the multi-cancer test mainly adds value for the cancers that have none.
— For a smoker, the proven lung CT is the higher-value move; the multi-cancer test is an unproven add-on, not a replacement.
— Whether a $949 blood test is worth it comes down to the numbers — how many people it actually helps versus alarms; this is how to read that.
— These multi-cancer blood tests are floated as an alternative to running separate screens like PSA.

Substance and claimed effects

Multi-cancer early detection (MCED) tests are blood-based assays that interrogate cell-free DNA (cfDNA) for a shared cancer signal across many tumour types. The dominant clinical product is GRAIL's Galleri, a targeted methylation assay launched in 2021 as a laboratory-developed test (LDT) under CLIA Klein et al. 2021. Other entrants — Exact Sciences Cancerguard, OncoSeek, several Chinese assays — share the broad paradigm but Galleri carries virtually all of the prospective evidence base. Claimed effects: detection of cancers without recommended screening (ovary, pancreas, oesophagus, stomach, liver, bile duct, head and neck) at earlier, more curable stages; reduction of late-stage and emergency presentations; complement (not replacement) of USPSTF-recommended screens. This entry covers the test's mechanism, its real-world performance at population scale, the false-positive cascade it triggers, current access and cost, and how to think about it given a still-evolving evidence base.

Evidence by addressing question

Mechanism

Dying tumour cells shed DNA fragments into the bloodstream through apoptosis, necrosis, and active secretion. These cfDNA fragments carry the tumour's epigenetic signature — most informatively, abnormal patterns of cytosine methylation in CpG islands. Two properties make methylation tractable as a multi-cancer signal: methylation aberrations are pervasive across tumour types (global hypomethylation plus locus-specific promoter hypermethylation is a near-universal hallmark of carcinogenesis), and methylation patterns are tissue-specific, so the same fragments that flag cancer also encode where it came from Klein et al. 2021.

Galleri sequences a targeted panel of the most informative methylation regions in cfDNA, then applies machine-learning classifiers trained on tens of thousands of paired cancer / non-cancer samples (the CCGA cohort, N=15,254) to produce two outputs: a binary cancer-signal-detected call, and — when positive — a Cancer Signal Origin (CSO) prediction naming one or two tissue candidates Klein et al. 2021. The biological floor for sensitivity is set by ctDNA shedding fraction: small early tumours (under 1 cm) shed too few fragments to clear the assay's detection threshold reliably. This is a physics problem, not an engineering one — it is the structural reason stage-I sensitivity is the hardest metric for any cfDNA-based MCED to achieve.

Evidence

Three large prospective datasets anchor the case for Galleri, plus one randomised trial whose primary endpoint just read out.

CCGA-3 (Klein 2021) — the registrational validation. N=4,077 (2,823 with confirmed cancer, 1,254 cancer-free), specificity 99.5%, overall sensitivity 51.5%. Stage-specific sensitivity: 16.8% stage I, 40.4% stage II, 77.0% stage III, 90.1% stage IV. CSO accuracy 88.7% among true positives Klein et al. 2021.

PATHFINDER (Schrag 2023) — the first prospective interventional study in asymptomatic adults. N=6,621 adults ≥50 in seven US health networks. Cancer signal detected in 1.4% of participants. PPV 38.0% with the original assay, 43.1% with the refined commercial version. Median time to diagnostic resolution: 57 days for true positives, 162 days for false positives. CSO first-or-second prediction was correct in 97% of cancer diagnoses. No serious adverse events were attributable to MCED testing itself Schrag et al. 2023.

PATHFINDER 2 (ESMO 2025) — registrational follow-up, N≈23,000. Cancer signal detection rate 0.93%, PPV 61.6%, specificity 99.6%, 12-month episode sensitivity 73.7% for the twelve deadliest cancers and 40.4% across all cancers. Stage I-II detected in 61 participants (≈3 per 1,000 screened, roughly half of all confirmed cancers in the cohort).

SYMPLIFY (Nicholson 2023) — the symptomatic-patient validation in NHS primary care. N=5,461 patients referred with suspected cancer. PPV 75.5%, specificity 98.4%, overall sensitivity 66.3% (24.2% stage I, 95.3% stage IV), CSO top-pick accuracy 85.2%. The high PPV reflects the higher pre-test probability in symptomatic populations — not screening performance Nicholson et al. 2023. Twenty-four-month follow-up published 2025 reclassified roughly one-third of apparent false positives as later-confirmed cancers, lifting PPV to 84.2%.

NHS-Galleri (ASCO 2026) — the world's first randomised controlled trial of MCED screening, N=142,250 adults aged 50–77, three annual screening rounds 2021–2024. Specificity 99.55%, PPV 52%, sensitivity 54.7% for twelve prespecified cancers and 30.7% across all cancers. The trial missed its primary endpoint — a statistically significant reduction in stage III/IV diagnoses. Stage IV diagnoses were reduced by 14% overall and ≈22-26% in the prespecified twelve; stage I-II diagnoses for those twelve rose 16%. Cancers found via symptomatic clinical presentation fell 21%; emergency presentations fell 25%. Mortality data are not yet mature NHS-Galleri 2026.

DETECT-A (Lennon 2020) — the earlier-generation CancerSEEK assay (mutation + protein, not methylation), N=10,006 women aged 65-75. Detected 26 cancers with PET-CT confirmation, with 99% specificity. Established the safety of an imaging-anchored false-positive workup; PPV was substantially lower than the methylation-era assays Lennon et al. 2020.

Across these studies, three patterns are stable: (i) specificity is consistently 98.4–99.6%, (ii) overall sensitivity ranges 30-66% depending on study population and case mix, (iii) stage-I sensitivity sits in the 10-25% range — far below what screening tests with mortality evidence (FIT, low-dose chest CT, mammography) achieve for their respective cancers.

Protocol

One venous blood draw (≈10 mL into Streck tubes), shipped to GRAIL's central lab, results returned in 10 working days. No fasting, no preparation. Suggested cadence in commercial materials is annual, modelled in cost-effectiveness analyses at age 50-79 with 90% adherence. The TRICARE coverage that opened in 2024 was initially annual; in mid-2025 it was restricted to once-per-lifetime, reflecting payer scepticism about the marginal value of repeat testing. A positive result triggers a CSO-directed diagnostic workup: imaging (PET-CT or whole-body MRI), targeted endoscopy or biopsy, follow-up labs.

Contraindications

No life-threatening contraindications — it is a blood draw. The functional contraindication is psychological: people with high baseline anxiety about cancer who would not act on a false positive without serious distress, and people whose result would not change their downstream behaviour. Pregnancy raises a real biological problem (placental cfDNA can produce a non-cancer methylation signal that the classifier may misread), and active haematologic disease similarly confounds the signal. Recent transfusion or transplant interferes with cfDNA interpretation for several weeks.

Misconceptions

Four pervasive misreadings of the marketing:

"Detects 50+ cancers" ≠ "screens for 50+ cancers at clinically useful sensitivity." Stage-I sensitivity for prostate and kidney is below 20%; whole-blood signal for brain primaries is effectively absent. The headline number is detection-when-present, not population-level case-finding power.
"99.5% specificity" ≠ "1 in 200 false positives among people screened." When the prior probability of cancer is low (asymptomatic 50-year-olds), the absolute false-positive count remains large relative to true positives — and around 38-52% of positive results across PATHFINDER and NHS-Galleri were not cancer.
An MCED-negative result is not a "clean bill." NPV of ≈98.9% in NHS-Galleri sounds reassuring but reflects the same low prior — it means most people without a positive truly are cancer-free, not that the test has ruled out cancer for the individual. Stage-I cancers are precisely the cases an MCED is most likely to miss NHS-Galleri 2026.
Stage shift ≠ mortality benefit. Reducing stage IV at diagnosis is biologically plausible as a precursor to mortality reduction, but lead-time bias and length bias both produce stage shift without saving lives. The NHS-Galleri primary endpoint — a statistically significant shift in late-stage diagnosis — was not met; mortality data are years away NHS-Galleri 2026.

Audience

Evidence base is concentrated in adults ≥50; pre-test probability of cancer rises with age, which is why MCED economics depend on screening older cohorts. PATHFINDER, NHS-Galleri, PATHFINDER 2 all enrolled ≥50; TRICARE coverage starts at 50. Below 40, the false-positive cascade dominates: cancer prior is so low that even at 99.5% specificity the PPV collapses. The clearer case for MCED is in adults 50+ with elevated risk: smoking history (20+ pack-years), strong family history (two or more first-degree relatives with cancer), known occupational exposure, or hereditary cancer syndromes. The case is weakest in low-risk under-50s for whom the test functions mostly as an anxiety amplifier.

Alternatives

The two policy alternatives are: (a) maximally adherent guideline-based single-cancer screening — USPSTF Grade A/B tests (colonoscopy or FIT, mammography, cervical screening, low-dose CT for lung in eligible smokers, prostate after shared decision-making) — which together cover the cancers responsible for roughly one-third of US cancer deaths and have mortality-reduction evidence USPSTF 2024; and (b) waiting for the FDA decision (GRAIL completed PMA submission January 2026) and the Medicare National Coverage Determination, both of which will reshape access and reimbursement. The "do MCED instead of guideline screening" framing is wrong — MCED's case is purely additive. Modelling work shows that one MCED on top of standard care produces 188× fewer follow-up procedures in cancer-free people than would adding ten new single-cancer screens Pangaluri et al. 2025.

Failure-modes

Five characteristic ways MCED testing fails an individual:

False positive → diagnostic odyssey. In PATHFINDER, 92% of CSO-positive participants underwent at least one imaging study; 30% of false-positive workups included an invasive procedure. Median time to "no cancer found" resolution was 162 days Schrag et al. 2023.
False negative → false reassurance. A negative MCED in someone with a real stage-I tumour delays symptomatic presentation; 196 of the 329 cancers found within twelve months of testing in PATHFINDER 2 were MCED-negative.
Mis-localised true positive. CSO is wrong in ≈8-15% of true positives, producing a diagnostic workup pointed at the wrong organ system before the real primary is found Pangaluri et al. 2025.
Indolent cancer detected and treated. Length-biased sampling enriches screen-detected cancers for slow-growing tumours; some fraction (unknown, but non-zero) of MCED-detected cancers would never have caused harm if left undetected.
Cumulative radiation exposure. Repeated PET-CT and CT workups from annual screening contribute non-trivially to long-term cancer risk in the absence of true disease Pangaluri et al. 2025.

Practicalities

List price $949; reduced self-pay typically $799; GRAIL financial assistance up to $350 off for qualifying low-income patients. Generally not covered by Medicare or private insurance pending FDA approval. TRICARE covers it for eligible service members aged 50+ with documented elevated risk (occupational exposure, ≥20 pack-year smoking history, strong family history), but as of mid-2025 limited the benefit to once per lifetime rather than annually. HSA/FSA eligible. Available only by clinician order — not direct-to-consumer in the US.

The downstream cost is not the test. A false-positive workup runs from a few hundred dollars (CSO-directed targeted imaging only) to several thousand (PET-CT, MRI, endoscopy, biopsy). Anecdotal practice patterns suggest patients with positive MCED results are often referred to specialty oncology clinics whose workup standards have not yet stabilised.

Stakes

Cancer mortality concentrated in cancers without screening — pancreatic, ovarian, oesophageal, liver, hepatobiliary — accounts for roughly two-thirds of US cancer deaths. The status quo case (no MCED) means these cancers continue to present symptomatically, often at stage III/IV, with five-year survival in the single digits for pancreatic and oesophageal. The skeptic reading of stakes: this hasn't changed in fifty years of intermittent screening innovation; the optimist reading: this is precisely the gap MCED is built to fill.

Payoff

The optimist payoff is a 14-26% reduction in stage IV diagnoses across the deadliest cancers, with downstream mortality benefit accruing 5-15 years out as those earlier-detected cancers move from incurable to surgically resectable. NHS-Galleri showed the stage shift at three years; mortality readout is pending. The pessimist payoff is null: the stage shift turns out to be largely lead-time and length bias, the absolute number of cancers that progressed to lethality is unchanged, and the screening adds cost and false-positive harm without saving lives. Current evidence is consistent with both — the trial that would resolve this hasn't reported mortality.

Out-of-scope

Not covered in this entry: tumour-informed minimal residual disease (MRD) testing in known cancer patients (Signatera, Natera Reveal, etc.) — different population, different question; single-cancer liquid biopsies (Shield, Cologuard Blood) — separate entries warranted; tissue-of-origin assays for cancers of unknown primary in symptomatic patients (GRAIL DAC) — different clinical scenario.

The credibility range

The optimist case

MCED is the first technology that can plausibly bend mortality curves for the cancers screening has never reached. The biology is sound: tumours shed methylated cfDNA, methylation is tissue-specific, and the signal is detectable in venous blood years before symptoms. Specificity is genuinely high (98-99.6% across every prospective study), and the safety of the false-positive cascade has been characterised: PATHFINDER, DETECT-A, and the NHS-Galleri PPV all show the diagnostic workup is bounded and resolvable. NHS-Galleri's three-year data — even with a missed primary endpoint — show the technology doing what it was designed to do: stage IV down 14-26% in the targeted cancers, emergency presentations down 25%, screen-detected cancers up four-fold. The mortality benefit is the question that hasn't been answered, but stage shift of this magnitude has historically presaged mortality reduction in mammography, low-dose CT, and FIT. Cost-effectiveness models project ≈0.1 QALY gain per Medicare beneficiary at lifetime adherence. Even if the test is misclassified as "marketing first, evidence second," the underlying technology will be FDA-reviewed in 2026-2027 and the price will collapse as competition arrives.

The skeptic case

The trial that was supposed to confirm MCED missed its primary endpoint. Stage shift is the cheapest surrogate in oncology — it captures lead-time bias and length-biased sampling by construction, and it has a long history of failing to translate to mortality (PSA, neuroblastoma mass screening). Stage-I sensitivity, the metric that matters most for actual early detection, is 10-25% across studies — meaning ≈80% of the cancers MCED is theoretically designed to catch at curable stage are missed. The false-positive cascade looks bounded in trial populations with extensive support infrastructure; rolled out at population scale through standard primary care, the workup burden — PET-CT exposure, invasive biopsy, months of "you might have cancer" anxiety — falls on tens of thousands of cancer-free patients per million screened. Galleri is an LDT — never FDA-reviewed, marketed aggressively in concierge-medicine and employer-benefits channels, priced at $949 annually with no insurance backstop. Medicare's NCD process for MCED has stalled because no trial has hit a primary endpoint. The PPV in symptomatic populations (SYMPLIFY 75-84%) is misleadingly applied to asymptomatic screening (PATHFINDER PPV 43-62%) in marketing materials. The reasonable position until mortality data arrives is: not ready for population deployment.

The author's call

The technology is real and the biology is sound. The clinical question — does MCED screening reduce cancer mortality at acceptable cost and harm — is genuinely unresolved. NHS-Galleri's missed primary endpoint is the central data point: the stage IV reduction is real but smaller than required to declare success on the trial's own pre-specified terms, and mortality readout is years out. For an asymptomatic average-risk adult under 50, the case is weak (low prior probability, high false-positive cost in absolute terms). For an adult 50+ with elevated risk (smoking, family history, occupational exposure), the case is plausible but unconfirmed — a reasonable decide-with-clinician call, paid out-of-pocket, with eyes open to the lead-time-bias possibility and the false-positive workup. The right framing is: this is one of the more interesting screening technologies in development; it is not yet a settled tool. Evidence: 2/5. Controversy: 4/5.

Stakeholder and incentive map

GRAIL (commercial). $7B+ in capital deployed, spun out of Illumina, market valuation depends on Medicare coverage. Heavy investment in NHS-Galleri, PATHFINDER, REACH (Medicare RWE study). Press releases routinely lead with the favourable subgroup endpoint and bury the missed primary.
Exact Sciences (Cancerguard), competitive MCED developers. Following GRAIL's regulatory path; benefit from any positive policy precedent.
Concierge medicine, employer wellness platforms. Major distribution channels at the consumer end; revenue share with GRAIL drives aggressive marketing to higher-income asymptomatic adults.
NHS, NIHR, DHA. The institutional payers who have either funded confirmatory trials (NHS) or extended coverage cautiously (DHA, TRICARE 2024 → 2025 retraction to once-per-lifetime).
USPSTF, Medicare. Holding the line on FDA approval and mortality evidence before recommendation / coverage. NCD process stalled.
Radiology professional bodies (ACR, RSNA). Sounding the alarm about diagnostic-workup burden, radiation exposure from PET-CT cascades, and the absence of standardised workup pathways Pangaluri et al. 2025.
Academic methodologists. The vocal skeptics — Welch, Prasad, the deceptive-screening-metrics literature — arguing the field is repeating the PSA and neuroblastoma mistakes.

Population variability

Three meaningful sources of variability:

Age and cancer prior. Test PPV scales with pre-test probability. At 50 the case for MCED is weaker than at 70; under 40, with cancer prevalence well below 1%, even a 99.5%-specificity test produces more false positives than true. NHS-Galleri restricted to 50-77; TRICARE 50+.
Risk-factor stratification. Smoking (≥20 pack-years), strong family history (two or more first-degree relatives with cancer), known occupational carcinogen exposure (Agent Orange, asbestos, burn pits), hereditary cancer syndromes — these raise pre-test probability enough to materially improve PPV.
Cancer-type heterogeneity. Sensitivity at stage I ranges from above 80% (oesophagus, ovary, pancreas — high ctDNA shedders) to below 20% (prostate, kidney) to effectively zero (brain primaries). The "50+ cancers screened" framing obscures that the test is much better at some than at others.

The cohorts that have driven validation are overwhelmingly white, US/UK, with limited representation of Black, Hispanic, and Asian populations; methylation patterns are likely population-stable but absolute baseline rates of cfDNA shedding are not yet characterised across ancestries. The REACH study is enrolling Medicare beneficiaries with explicit attention to historically underrepresented communities.

Knowledge gaps

Mortality benefit. The central unknown. NHS-Galleri will accrue mortality follow-up through ≈2030. No other RCT will read out sooner.
Overdiagnosis fraction. Unknown what proportion of MCED-detected cancers would never have caused harm. Indolent tumours of the kidney, prostate, thyroid, and some breast and lung cancers are the obvious candidates.
Optimal cadence. Annual vs biennial vs once-per-lifetime is unresolved; TRICARE's 2025 retraction to once-per-lifetime reflects the absence of evidence for repeat testing benefit.
Standardised workup pathways. No professional consensus on how to investigate a CSO-positive result. Practice patterns vary substantially.
Performance in high-risk populations. The test was validated in mixed-risk cohorts; performance in BRCA carriers, Lynch syndrome, heavy smokers, post-cancer survivors is undercharacterised.
FDA decision and Medicare NCD. Both pending. PMA submission completed January 2026; first decisions expected 2026-2027.

Scoping. The brief named four consequences (early-stage detection, false-positive rate, follow-up imaging burden, current evidence and access). All four are covered end-to-end in the article. Substance is the technology class as a whole, anchored on Galleri because it carries virtually all of the prospective evidence base; Cancerguard, OncoSeek and the Chinese assays get only passing mention since published data on them is thin.

Action. Chose decide over test. test would frame this as a no-brainer "gather your data" intervention; the contested evidence base, $949 list price, and missed primary endpoint make this a tradeoff that warrants clinician input.

Hard rating calls.

longevity = 1. NHS-Galleri showed a real stage shift but missed its pre-specified primary endpoint, and the mortality readout is ≈2030. Scoring 2 ("real but small contribution") would over-claim before mortality lands; scoring 0 would deny that some people with curable-stage cancers are being caught. 1 reflects the marginal, contested, not-yet-confirmed contribution.
evidence = 2. Three large prospective cohorts plus one near-miss RCT could justify 3 on volume alone, but the missed primary endpoint, FDA non-approval, USPSTF non-recommendation, and absent mortality data put this firmly in "sparse/contested with plausible mechanism" territory.
controversy = 4. Deliberately high. Proponents and skeptics genuinely disagree on whether stage shift will translate to mortality benefit; not just minor pushback at the margins.
cost_burden = 3. If TRICARE's once-per-lifetime model becomes the norm, this drops to 2. Scored as the marketed annual-screening cadence — $949 × years.

Audience scoping. Restricted to ages 40-59 and 60+. All major studies enrolled ≥50, marketed/covered at 50+, and the pre-test probability arithmetic makes the test substantially weaker under 40. Including 18-39 would mislead.

Contraindications. Pregnancy is the one closed-vocabulary token that genuinely applies (placental cfDNA confounds the assay). Active haematologic disease, recent transfusion/transplant, and severe cancer anxiety are flagged in the warning callout but don't map to vocabulary tokens.

Separate-entry candidates. Individual USPSTF-recommended screens (colorectal screening, mammography, low-dose chest CT, cervical screening, PSA) each warrant their own entry. Hereditary cancer syndrome genetic testing (BRCA, Lynch) is a separate substance with separate evidence. Tumour-informed MRD testing (Signatera, Natera Reveal) is a different clinical question and a separate entry; deliberately excluded here and signposted in out-of-scope.

Future links to wire in. When the entries above exist: colonoscopy/FIT, mammography, low-dose CT for lung cancer screening, hereditary cancer genetic testing, MRD monitoring.

Timely. NHS-Galleri full results were presented at ASCO 2026 (May 29 – June 2, 2026). This article was written ≈48 hours after results dropped; mortality follow-up will reshape the entry by ≈2030. The longevity score and the framing throughout (especially evidence + payoff) should be revisited when the mortality data publish.

What was deliberately left out. Detailed performance breakdowns by individual cancer type (would have read as a literature review); DETECT-A / CancerSEEK history (technically interesting precursor, present in research dossier but not in reader prose); cost-effectiveness modelling specifics (QALY/LY numbers are too sensitive to model assumptions to anchor reader prose on).